Status
Conditions
Treatments
About
This study aims to confirm that the benefit-risk assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) remains positive in real-world use and to ensure the adequacy of the TAMBE Device training program.
Full description
A maximum of 300 adult subjects will be enrolled at up to 60 U.S. centers, with a minimum of 70 subjects enrolled at study centers with no prior experience using the TAMBE Device. Subjects will have follow-up at 1 month, 6 months, 12 months and annually thereafter through 10 years post implant.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
The subject is / has:
Exclusion criteria
The subject is / has:
Primary purpose
Allocation
Interventional model
Masking
300 participants in 1 patient group
Loading...
Central trial contact
Nickole Garvey; Megan Mitchell
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal